Loading clinical trials...
Loading clinical trials...
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Conditions
Interventions
Etavopivat
Placebo
Locations
172
United States
Uni of Alabama at Birmingham
Birmingham, Alabama, United States
Univer South Alabama Ped/Onc
Mobile, Alabama, United States
Phoenix Children's Hsptl
Phoenix, Arizona, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California, United States
UCLA Health
Los Angeles, California, United States
Start Date
February 17, 2025
Primary Completion Date
August 27, 2027
Completion Date
March 12, 2029
Last Updated
April 24, 2026
NCT06820515
NCT07392216
NCT04416178
NCT05359991
NCT05431088
NCT05170412
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions